Connect with us


Hospital In Jabalpur Offers Cheap treatment Of Brain Aneurysm

Brain aneurysm is also treated by surgery, in which there is a high risk, and can be fatal.



JABALPUR (Madhya Pradesh): The treatment of brain aneurysm through coiling for the general public has been started at discounted rates at the Super Specialty Hospital of Netaji Subhash Chandra Medical College, Jabalpur. This facility is available in very limited institutions in the country.

The treatment of brain aneurysm usually costs around Rs 5 to 8 lakhs depending on the number of coils and stents.

Aneurysm is the state of the blood vessels of the brain in which blood vessels rupture due to weakening of the wall.

In most cases, lack of treatment leads to death of the patient. If not treated at the right time, frequent bleeding occurs, which causes unbearable pain to the patient.

Brain aneurysm is also treated by surgery, in which there is a high risk, and can cause the death of the patient.

Treatment of brain aneurysm through coiling is a low-risk treatment similar to angioplasty. This technique is much better than treatment through medicines.

The hospital’s head of the department, Dr Pradeep Kasar said that with the help of the government, the facility of treatment of diseases available in big cities is now being provided in government hospitals of the state.

Brain stroke is also being treated at the Super Specialty Hospital, Jabalpur, in which the blood clots are removed by mechanical method. This method is much better than the treatment of medicines.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.


Coronavirus: 7 Indian Airports To Have Thermal Screening Of Arrivals From China, HK

In-flight announcements to be made requesting passengers with a history of fever and cough and travel to Wuhan City.



NEW DELHI: Thermal Screening of passengers arriving from China including Hong Kong has expanded to seven airports in view of the threat of Novel Corona Virus Disease in Wuhan, China.

These airports are Delhi, Mumbai and Kolkata, Chennai, Bengaluru, Hyderabad and Cochin.

Civil Aviation Ministry has directed for all logistics support and arrangements to be made immediately with regard to screening of passengers arriving in India from China including Hong Kong.

The Ministry has called for immediate implementation of the action plan and strict adherence by identified airports and all concerned airlines.

In order to facilitate early isolation, in-flight announcements to be made by the airlines requesting passengers with a history of fever and cough and history of travel to Wuhan City in last 14 days.

All passengers and crew who are healthy should be allowed to continue their onward journey.

If the ill passenger or crew member is confirmed as a probable case of Wuhan Corona Virus, public health authorities should be notified about the contacts using the Passenger Locator Form.

Operational procedures recommended by the International Air Transport Association (IATA) with regard to managing the suspected communicable disease on board an aircraft. All passengers and crew who are otherwise healthy should be allowed to continue their onward journey. If the ill passenger or crew member is confirmed as a probable case of Wuhan Corona Virus, public health authorities should be notified about the contacts using the Passenger Locator Form,” the government’s advisory said.

Several countries have increased checks at airports to detect the symptoms of the coronavirus which first emerged in the Chinese city of Wuhan.

Indian carriers like Air India, IndiGo, SpiceJet connect India and Hong Kong among other global airlines.

As far as China is concerned, Indigo and Air India are the two Indian carriers, other than China Southern, Air China and other airlines.

The outbreak of the virus comes when millions of Chinese travel to their hometowns and overseas to celebrate Lunar New Year, which is also called by many as the world’s biggest annual mass migration.

Continue Reading


Polio Vaccination NOW Causing More Infections than Wild Virus?

In rare instances, the live virus in oral polio vaccines can mutate and become infectious, causing new outbreaks.



LONDON (England): — Nigeria, Democratic Republic of Congo, Central African Republic, and Angola have reported new cases of polio linked to the oral vaccine, as global health numbers show there are now more children being paralyzed by viruses originating in vaccines than in the wild.

In a report late last week, the World Health Organization and partners noted nine new polio cases caused by the vaccine in the four countries.

Seven countries elsewhere in Africa have similar outbreaks and cases have been reported in Asia. Of the two countries where polio remains endemic, Afghanistan and Pakistan, vaccine-linked cases have been identified in Pakistan.

In rare cases, the live virus in oral polio vaccine can mutate into a form capable of sparking new outbreaks.

All the current vaccine-derived polio cases have been sparked by a Type 2 virus contained in the vaccine.

Type 2 wild virus was eliminated years ago.

Polio is a highly infectious disease that spreads in contaminated water or food and usually strikes children under 5. About one in 200 infections results in paralysis. Among those, a small percentage die when their breathing muscles are crippled.

Donors last week pledged $2.6 billion to combat polio as part of an eradication initiative that began in 1988 and hoped to wipe out polio by 2000. Since then, numerous such deadlines have been missed.

To eradicate polio, more than 95% of a population needs to be immunized. WHO and partners have long relied on oral polio vaccines because they are cheap and can be easily administered, requiring only two drops per dose. Western countries use a more expensive injectable polio vaccine that contains an inactivated virus incapable of causing polio.

The Independent Monitoring Board, a group set up by WHO to assess polio eradication, warned in a report this month that vaccine-derived polio virus is “spreading uncontrolled in West Africa, bursting geographical boundaries and raising fundamental questions and challenges for the whole eradication process.”

The group said officials were already “failing badly” to meet a recently approved polio goal of stopping all vaccine-derived outbreaks within 120 days of detection. It described the initial attitude of WHO and its partners to stopping such vaccine-linked polio cases as “relaxed” and said “new thinking” on how to tackle the problem was needed.

Continue Reading


New Rotavirus Vaccine ROTAVAC-5D® Launched By Vice President Naidu

Rotavirus causes approximately 200,000 deaths and about 2 million hospitalizations annually across the world.



NEW DELHI: Vice President M Venkaiah Naidu on December 3 launched the new Rotavirus vaccine ROTAVAC-5D®, a smaller dosage form of its earlier oral immunisation shot that can be stored at a relatively higher temperature, in New Delhi.

There is a need for vaccination at the right time. While the government is doing its best on this front, it is a greater social responsibility which every medical professional should take forward besides removing apprehension about vaccination for timely prevention of diseases. This would ensure better health of the nation and its people,” said Naidu in his speech.

Designed and developed by Bharat Biotech, it is available in a 0.5 ml dosage, Rotavac 5D can be stored at 2-8 degree Celsius for up to 24 months, and can be administered in five drops. Rotavac 5D is also stable at 37 degree Celsius for seven days.

In contrast, the earlier version, Rotavac is available in 2.5 ml vial per dose and has to be stored at -20 degree Celsius.

The vaccine stability, combined with its small cold chain footprint, enables its use in low resource settings and outreach programs, the company said in a release.

On the occasion, the Vice President said that he believed that ROTAVAC is an example of a true social innovation that was realized through a partnership between scientists from India and the USA.

He added that India is committed to the goal of protecting the health of each and every one of its children.

Vice President added that India is firmly committed to ending morbidity and mortality in children caused due to diarrhoea by 2022.

The first generation, Rotavirus vaccine, ROTAVAC developed under a Public-Private Partnership with the Department of Biotechnology, Govt. of India, has put India on the global map for setting new standards in pharmaceutical Research and Development.

Rotavac 5D has been evaluated in clinical trials in India and other countries. This vaccine is safe, effective and affordable, besides being cross-protective against a variety of rotavirus strains.

Its efficacy compares favourably with the efficacy of the currently licensed rotavirus vaccines in low-resource countries. The study results showed clear evidence of protection across different rotavirus strains and continued efficacy in the second year of life. Currently, over 25 countries have granted patents for Rotavac 5D.

The company invested US$ 20 million to develop new manufacturing facilities and supporting infrastructure in its Genome Valley plant in Hyderabad with an installed manufacturing capacity of 200 million doses per year. The project was supported in part by the Bill and Melinda Gates Foundation.

Globally rotavirus disease burden is estimated at 200,000 deaths and two million hospitalisations annually, mostly in low-income countries. Prevention of rotavirus infections would lead to a significant reduction in infant mortality rates and reduce the economic impact of hospitalisations to national governments across the globe.

Continue Reading

Most Read This Month

error: Content on this news portal is protected!